When was Mirum Pharmaceuticals founded?

Mirum Pharmaceuticals was founded in 2018 and raised its 1st funding round within a year of its incorporation.

Where is Mirum Pharmaceuticals located?

Mirum Pharmaceuticals is headquartered in Menlo Park, United States. It is registered at Menlo Park (United States).

Who is the current CEO of Mirum Pharmaceuticals?

Christopher Peetz of Mirum Pharmaceuticals.

How many employees does Mirum Pharmaceuticals have?

As of Sep 30, 2026, the latest employee count at Mirum Pharmaceuticals is 506.

Is Mirum Pharmaceuticals a funded company?

Mirum Pharmaceuticals is a funded company, having raised a total of $120M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Nov 07, 2018.

When was the latest funding round of Mirum Pharmaceuticals?

Mirum Pharmaceuticals' latest funding was a $***** Post IPO round on Jan 23, 2026, with participation from 0 investor.

What is the annual revenue of Mirum Pharmaceuticals?

Annual revenue of Mirum Pharmaceuticals is between $500M and $1B as on Dec 31, 2025

Where does Mirum Pharmaceuticals rank among its competitors?

Mirum Pharmaceuticals ranks 11th amongst 236 active competitors, of which 80 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Drug Farm, which secured $55M in Jul, 2026.

Who are the top competitors of Mirum Pharmaceuticals?

Mirum Pharmaceuticals' top competitors include BioMarin Pharmaceutical, Ultragenyx and Nimbus Therapeutics. Among them, Drug Farm secured the most recent funding round in July, 2026.

Mirum Pharmaceuticals - 2026 Company Profile, Team, Funding, Competitors & Financials

Mirum Pharmaceuticals is a public company based in Menlo Park (United States), founded in 2018. It operates as a Developer of small molecule based therapeutics to treat rare diseases. Mirum Pharmaceuticals has raised $120M in funding from New Enterprise Associates. The company has 236 active competitors, including 80 funded and 72 that have exited. Its top competitors include companies like BioMarin Pharmaceutical, Ultragenyx and Nimbus Therapeutics.

Company Details

Developer of small molecule based therapeutics to treat rare diseases. The company's lead product candidate Maralixibat inhibits a carrier protein called apical sodium-dependent bile acid transporter for reducing systemic levels of bile acids. It is used for the treatment of both Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis. The other product of the company Volixibat is used for the treatment of adult cholestasis.

Website: mirumpharma.com
Social
Email ID: *****@mirumpharma.com
Phone Number: +1 **********
Registered Address: Menlo Park (United States)

Key Metrics

Founded Year

2018

Location

Menlo Park, United States

Stage

Public

Total Funding

$120M in 3 rounds

Latest Funding Round

Post IPO, Jan 23, 2026, $*****

Investors

New Enterprise Associates & 10 more

Ranked

11^th among 236 active competitors

Annual Revenue

$500M - $1B as on Dec 31, 2025

Employee Count

506 as on Sep 30, 2026

Investment & Acquisitions

Bluejay Therapeutics & 1 more

Similar Companies

BioMarin Pharmaceutical & 213 more

Exit Details

Public

View Mirum Pharmaceuticals' full profile

Mirum Pharmaceuticals is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Mirum Pharmaceuticals, Inc. CIN: 7258165 , United States, Active	Feb 16, 2024	-	-	-
Mirum Pharmaceuticals, Inc. CIN: 1759425 , United States, Active	May 01, 2018	$500M - $1B (As on Dec 31, 2025)	196 (As on Dec 31, 2022)	-
Mirum Pharmaceuticals, Inc. CIN: 1759425 , Belgium, Active	Dec 31, 2017	-	137 (As on Dec 31, 2021)	-

Mirum Pharmaceuticals got listed on Jul 18, 2019.

Click here to take a look at Mirum Pharmaceuticals's IPO in detail

Mirum Pharmaceuticals has raised a total funding of $120M over 3 rounds. Its first funding round was on Nov 07, 2018. Mirum Pharmaceuticals has 11 institutional investors.

Here is the list of recent funding rounds of Mirum Pharmaceuticals:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 23, 2026	9927621	Post IPO	1639181	3394664	4660661	1359883
Dec 30, 2020	7413946	Post IPO	6642635	9469531	2055718	Oberland Capital
Nov 07, 2018	3494063	Series A	1141119	3296018	New Enterprise Associates	Deerfield & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Mirum Pharmaceuticals's funding rounds and investors

Mirum Pharmaceuticals' employee count trend

Mirum Pharmaceuticals has 506 employees as of Sep 26. Here is Mirum Pharmaceuticals's employee count trend over the years:

Employee count trend for Mirum Pharmaceuticals

Uncover Mirum Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Mirum Pharmaceuticals include BioMarin Pharmaceutical, Ultragenyx and Nimbus Therapeutics. Here is the list of Top 10 competitors of Mirum Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BioMarin Pharmaceutical 1997, San Rafael (United States), Public	Developer of therapeutics for the treatment of rare genetic diseases	$37.5M	Temasek, The Grosvenor Funds & 7 others	72/100
2nd	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 10 others	69/100
3rd	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
4th	Madrigal Pharmaceuticals 2011, Conshohocken (United States), Acquired	Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis	$38.4M	HarbourVest Partners, Avoro Capital & 3 others	66/100
5th	Mammoth 2017, Brisbane (United States), Series D	Provider of molecular diagnostics platform by using CRISPR technology	$271M	Redmile Group, Decheng Capital & 34 others	65/100
6th	Drug Farm 2015, Shanghai (China), Series D	Developer of a novel treatment for metabolic diseases	$138M	Shanghai Pudong Leading Area Investment Center, Zhejiang Private Enterprise United Investment ... & 13 others	64/100
7th	CRISPR Therapeutics 2013, Basel (Switzerland), Public	Developer of solutions for treating human genetic diseases by using genome editing technology	$127M	Celgene, New Leaf Venture Partners & 10 others	63/100
8th	AIRNA 2021, Cambridge (United States), Series B	Developer of gene therapies for rare and common diseases	$245M	Forbion, Arch Venture Partners & 9 others	63/100
9th	Intercept Pharmaceuticals 2002, New York City (United States), Acquired	Developer of therapeutics to treat progressive non-viral liver diseases	$121M	Orbimed, JAFCO Group & 7 others	63/100
10th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Gilde Healthcare, Advent Life Sciences & 11 others	62/100
11th	Mirum Pharmaceuticals 2018, Menlo Park (United States), Public	Developer of small molecule based therapeutics to treat rare diseases	$120M	Oberland Capital, Frazier Life Sciences & 9 others	63/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Mirum Pharmaceuticals's competitors? Click here to see the top ones

Mirum Pharmaceuticals has acquired 2 companies including Bluejay Therapeutics and Satiogen. Mirum Pharmaceuticals has not made any investments as of now.

Here is the latest report on Mirum Pharmaceuticals's sector:

Free

Metabolic Diseases - Sector Report

Edition: September, 2026 (67 Pages)

View all reports related to Mirum Pharmaceuticals

Media has covered Mirum Pharmaceuticals for a total of 40 events in the last 1 year, 20 of them have been about company updates and 2 about people movement.